









Markets
/
Stocks
/
nasdaq-thar
/

Tharimmune Inc

THAR

3.600USD

+0.940+35.34%

Close 09/19, 16:00（ET）Quotes delayed by 15 min

15.20MMarket Cap

LossP/E TTM



Tharimmune Inc

3.600

+0.940+35.34%

Overview Company Financials Analysis

TradingKey Stock Score

Overall Financial Health

Valuation Dimensions

Earnings Forecast

Price Momentum

Institutional Confidence

Risk Assessment

Peer Comparison

TradingKey Stock Score

Currency: USD Updated: 2025-09-19

Key Insights

Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a . The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Industry Ranking

306 / 506

Overall Ranking

588 / 4720

Industry

Biotechnology & Medical Research

Support & Resistance

No Data

Score Analysis

Current score

Previous score

Analyst Rating

Based on 0 analysts

Current Rating

5.000

Target Price

+87.97%

Upside Space

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Company Highlights

StrengthsRisks

Tharimmune, Inc. is a clinical-stage biotechnology company. The Company is engaged in developing a portfolio of therapeutic candidate for inflammatory and immunologic conditions. It has a transmucosal film product, TH104 in Phase I clinical development, two bispecific candidates and a Picobody candidate in pre-clinical development. TH104 is a transmucosal buccal film embedded with the active compound nalmefene onto a thin film which adheres inside of the mouth on the cheek and biodegrades. TH104 is an ideal product candidate for multiple liver-related and other pruritogenic inflammatory conditions. It is also developing an early-stage pipeline of novel therapeutic candidates targeting validated high value immune-oncology (IO) targets including human epidermal growth factor (EGF) receptor 2 (HER2), human EGF receptor 3 (HER3) and programmed cell death protein (PD-1). The Company is developing antibodies, including bispecific antibodies, antibody drug conjugates (ADCs) and others.

High Profit Growth

The company's net income leads the industry, with the latest annual income totaling USD 43.95.

Undervalued

The company’s latest PE is -0.59, at a low 3-year percentile range.

Institutional Buying

The latest institutional holdings are 1.13M shares, increasing 31.80% quarter-over-quarter.

Held by James Simons

Star Investor James Simons holds 0.00 shares of this stock.

Higher Market Activity

The company has more investor interest, with a 20-day turnover ratio of 0.38.

Financial Health

Currency: USD Updated: 2025-09-19

There is no financial score for this company; the Biotechnology & Medical Research industry's average is 6.93.

Score

Industry at a Glance

Previous score

0.00

Change



Financials



Key Metrics

Cash and cash equivalents

Total assets

Total liabilities

Free cash flow

No Data



Quality of Earnings



Key Metrics

Total revenue

Operating profit

Total assets

SG&A

No Data



Operational Efficiency



Key Metrics

Cash flow from operating activities

Income after tax

No Data



Growth Potential



Key Metrics

Cash flow from operating activities

Total revenue

No Data



Shareholder Returns



Key Metrics

Free cash flow

No Data

Company Valuation

Currency: USD Updated: 2025-09-19

The company’s current valuation score is 2.80, which is lower than the Biotechnology & Medical Research industry's average of 3.06. Its current P/E ratio is -0.44, which is -67.03% below the recent high of -0.14 and -10.03% above the recent low of -0.48.

Score

Industry at a Glance

Previous score

2.80

Change

Valuation Dimensions

P/E

P/B

P/S

P/CF

Industry Ranking 306/506

No Data

Earnings Forecast

Currency: USD Updated: 2025-09-19

There is no earnings forecast score for this company; the Biotechnology & Medical Research industry's average is 8.03. The average price target for Tharimmune Inc is 5.00, with a high of 5.00 and a low of 5.00.

Score

Industry at a Glance

Previous score

0.00

Change

Support & Resistance

No Data

No Data

Financial Forecasting

EPS

Revenue

Net Profit

EBIT

No Data

Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.

Price Momentum

Currency: USD Updated: 2025-09-19

The company’s current price momentum score is 3.78, which is lower than the Biotechnology & Medical Research industry's average of 6.58. Sideways: Currently, the stock price is trading between the resistance level at 6.98 and the support level at 0.44, making it suitable for range-bound swing trading.

Score

Industry at a Glance

Previous score

3.78

Change

0.14

Support & Resistance

No Data

Indicators



The Indicators feature provides value and direction analysis for various instruments under a selection of technical indicators, together with a technical summary.

This feature includes nine of the commonly used technical indicators: MACD, RSI, KDJ, StochRSI, ATR, CCI, WR, TRIX and MA. You may also adjust the timeframe depending on your needs.

Please note that technical analysis is only part of investment reference, and there is no absolute standard for using numerical values to assess direction. The results are for reference only, and we are not responsible for the accuracy of the indicator calculations and summaries.

Indicators

Sell(2)

Neutral(3)

Buy(2)

Indicators

Value

Direction

MACD(12,26,9)

-0.391

Neutral

RSI(14)

53.078

Neutral

STOCH(KDJ)(9,3,3)

43.847

Buy

ATR(14)

0.620

Low Volatility

CCI(14)

-12.644

Neutral

Williams %R

67.278

Sell

TRIX(12,20)

0.033

Sell

StochRSI(14)

100.000

Buy

Moving Average

Sell(1)

Neutral(0)

Buy(5)

Indicators

Value

Direction

MA5

2.952

Buy

MA10

2.983

Buy

MA20

4.148

Sell

MA50

2.630

Buy

MA100

2.084

Buy

MA200

1.910

Buy

Institutional Confidence

Currency: USD Updated: 2025-09-19

The company’s current institutional recognition score is 3.00, which is lower than the Biotechnology & Medical Research industry's average of 5.96. The latest institutional shareholding proportion is 24.46%, representing a quarter-over-quarter increase of 75.61%. The largest institutional shareholder is James Simons, holding a total of 0.00 shares, representing 0.00% of shares outstanding, with 100.00% decrease in holdings.

Score

Industry at a Glance

Previous score

3.00

Change

Institutional Shareholding

No Data

Shareholder Activity

Name

Shares Held

Chg %

Gravitas Capital LP

732.42K

+85.62%

GSB Holdings, Inc.

166.59K

Clarke (David Howard)

35.00K

Appajosyula (Sireesh)

62.27K

+7894.22%

Bounty Hunter LLC

47.60K

Geode Capital Management, L.L.C.

15.37K

+123.60%

Risk Assessment

Currency: USD Updated: 2025-09-19

The company’s current risk assessment score is 3.09, which is lower than the Biotechnology & Medical Research industry's average of 3.33. The company's beta value is 1.51. This indicates that the stock tends to outperform the index during upward trending markets but experiences larger declines during downward trending markets.